bpc 157 works orally BPC-157 ORAL BPC 157 is the injury
Description
In 2023, the FDA designated BPC-157 as a Category 2 bulk drug substance, meaning it cannot be compounded by commercial pharmaceutical companies, and there is insufficient evidence regarding potential harm to humans
This happens because Metformin affects the calcium-dependent pathway necessary for B12 uptake
The content on our platform is for informative purposes only, and may not cover all clinical/non-clinical aspects
Additionally, they were able to show that activation of mast cells in osteoarthritis is through IgE/FcRI
